ENTA - Enanta Pharmaceuticals, Inc.
About Enanta Pharmaceuticals, Inc. (https://www.enanta.com)
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Scott T. Rottinghaus | Chief Medical Officer | 1974 | $863,706 USD |
| Yat Sun Or | Chief Scientific Officer | 1952 | $814,285 USD |
| Jay R. Luly | President, Chief Executive Officer & Director | 1956 | $742,273 USD |
| Nathaniel S. Gardiner | Consultant | 1954 | $672,675 USD |
| Brendan Luu | Chief Business Officer | 1975 | $622,856 USD |
| Matthew Kowalsky | Chief Legal Officer & Corporate Secretary | 1973 | $575,652 USD |
| Tara Lynn Kieffer | Chief Product Strategy Officer | 1978 | $496,852 USD |
| Harry R. Trout | VP of Finance & Interim Principal Financial Officer | 1969 | – |
| Jennifer Viera | Executive Director of Investor Relations & Corporate Communications | – | – |
| Kathleen S. Capps | Executive Director of Accounting, Controller & Interim Principal Accounting Officer | 1985 | – |